Montreal, QC, Canada (Jun 17, 2025) – 35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, today announced that it has been selected to receive the 2025 Gold Leaf Award for “Promising Biotech Company of the Year” from BIOTECanada.
“We are grateful to receive the Gold Leaf Award for Promising Biotech Company of the Year by BIOTECanada. This recognition is a testament to the tireless commitment, scientific creativity, and executional excellence of the entire 35Pharma team, and I’m extremely proud of what we have accomplished to date,” said Ilia A. Tikhomirov, Chief Executive Officer of 35Pharma. “Through our deep expertise in TGF‑beta superfamily biology and design and development of complex protein therapeutics, we’ve built a differentiated platform of multi-specific and highly selective Activin and GDF ligand traps that could become transformative therapies for heart failure, obesity and pulmonary hypertension.”
BIOTECanada’s Gold Leaf Awards, presented annually at BIO International, recognize the remarkable individuals and companies who have made significant contributions to the biotech industry in Canada. The ”Promising Biotech Company of the Year” Award is an award designed to recognize small and mid-sized pre-commercial companies that have set themselves apart from their peers through exceptional achievements and forward-thinking approaches. The 2025 Gold Leaf Award honorees will be celebrated at BIO International, taking place in Boston from June 16th – 19th, 2025.
About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company focused on developing best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for pulmonary hypertension, obesity and cardiometabolic diseases. 35Pharma leverages its scientific leadership in TGF-beta biology, combined with superior protein engineering, to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta superfamily ligands, while sparing beneficial homeostatic ligands. For more information, please visit www.35pharma.com
Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com
